Searched for
SEMAGLUTIDE PIPELINE
India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...
- Weight-loss drug semaglutide set to get cheaper as generic wave builds in IndiaPrices for generic semaglutide, a popular weight-loss drug, are expected to fall by more than half in the coming months. This sharp decline...
- Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh inDr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared w...
- Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billionBiocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as success...
- Emcure eyes India growth, global deals amid strong demandEmcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in I...
- RPG Life Sciences bets big on API business, eyes GLP-1 entry by August-SeptemberRPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company a...
- Dr Reddy’s shares fall 2% after Goldman Sachs downgrades, Citi turns cautiousDr Reddy’s shares fell after Goldman Sachs and Citigroup turned cautious, citing limited growth visibility, pipeline concerns and valuation...
- Social media is abuzz with weight-loss drug retatrutide and longevity goals. What is the drug all about?A new weight-loss drug, retatrutide, is generating excitement. This investigational medicine targets three hormone receptors, offering a po...
- Ajanta Pharma, Sun Pharma poised to tap GLP-1 opportunity amid market shift: Siddhartha KhemkaIndia's metabolic therapy market is transforming post-semaglutide patent expiry, shifting to a competitive, volume-driven model. With signi...
- Eli Lilly sticks to premium pricing for its innovator drug ahead of generics waveEli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite ...
- Liraglutide still a ‘decent market’ despite Novo’s price moves: Siddharth Mittal, BioconBiocon CEO Siddharth Mittal outlines the company's strategy in the competitive GLP-1 market. Focusing on liraglutide's launch in the US and...
- Dr Reddy's shares jump 5% despite 14% YoY fall in Q3 profit. Should you buy, sell or hold?Dr Reddy's shares: The company posted a 14% year-on-year decline in consolidated net profit to Rs 1,210 crore.
- Drug maker Lupin inks licensing pact with Galenicum for injectable SemaglutideDrug maker Lupin announced a significant partnership. Its subsidiary, Lupin Atlantis Holdings SA, has signed an agreement with Galenicum He...
- Dr Reddy’s gets nod to make generic semaglutide for weight lossDr Reddy's Laboratories is set to launch generic semaglutide, a popular weight loss drug. An expert committee has approved their proposal. ...
- Weight-loss drugs: Indian giants Dr Reddy’s to Macleods start preparing for Ozempic patent expiryIndian companies are gearing up to produce ingredients for generic weight-loss drugs. Novo Nordisk's patents are expiring soon. Dr Reddy's ...
- Novo Nordisk to test weight-loss drugs in broader range of obesity-linked conditionsNovo Nordisk is broadening its focus beyond obesity and diabetes by exploring the potential of its weight-loss drugs, including Wegovy, to ...
- Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEODr. Reddy's Laboratories is closely monitoring a potential US tariff on the pharma sector, viewing it as both a risk and opportunity. The c...
Load More
